|Bid||58.87 x 1000|
|Ask||58.88 x 1000|
|Day's Range||58.79 - 60.24|
|52 Week Range||40.68 - 60.24|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||32.66|
|Forward Dividend & Yield||0.84 (1.41%)|
|Ex-Dividend Date||Nov 25, 2019|
|1y Target Est||N/A|
Shares of Perrigo Co. Plc rallied about 9% on Tuesday, after Leerink said sales guidance offered earlier in the day was strong. The company said it expects sales to total about $1.3 billion for the fourth quarter and $4.8 billion for the full year, both numbers above consensus. In a statement released ahead of an investor conference, the Dublin-based company said it had an "outstanding" fourth quarter. "All business segments delivered stellar fourth quarter net sales results with strong organic growth," the company said. Leerink analysts led by Ami Fadia said the numbers were "particularly strong even for the seasonally best quarter." Perrigo management are expected to offer further details at the conference around 4.30 Eastern time. The company is expected to release full fourth-quarter earnings in the fourth week of February. Leerink rates the stock market perform. Shares have gained 20% in the last 12 months, while the S&P 500 has gained 27%.
Perrigo Co. Plc said Tuesday it expects 2019 sales to come to $4.8 billion, up 2% from the year-earlier period and ahead of the $3.98 billion FactSet consensus. In a statement released ahead of an investor conference, the Dublin-based company said it had an "outstanding" fourth quarter. "All business segments delivered stellar fourth quarter net sales results with strong organic growth," the company said. Worldwide Consumer sales came to about $3.9 billion, up 2% from the year-earlier period. Consumer Self-Care Americas sales came to about $2.5 billion. Consumer Self-Care International sales came to about $1.4 billion, down 1%, while the drug segment sales came to about $970 million for a gain of about 5%. Shares rose 2.7% premarket and have gained about 10.5% in the last 12 months, while the S&P 500 has gained 27%.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Perrigo Company plc...
Is Perrigo Company (NASDAQ:PRGO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
With the 2010s officially drawing to a close, Yahoo Finance took a look at some of the biggest S&P 500 winners and losers of the past decade based on price returns.
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the branded over-the-counter (OTC) rights to Prevacid®24HR.
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling. Takeaways From ...
Witi, a producer of medical-grade vaporization devices, announced Thursday it has partnered with Perrigo (NYSE: PRGO) to create a new smoking cessation product. The two companies plan to work on an electronic nicotine delivery system that would later be submitted for approval by the FDA and other international regulatory agencies. Perrigo is a dominant figure in nicotine replacement therapy, with a plethora of products intended to help smokers quit.
Shares of Ionis Pharma jumped Wednesday after the biotech's third-quarter sales and profit easily topped Wall Street's estimates. But Perrigo and Elanco stocks dipped after their reports.
Perrigo (PRGO) delivered earnings and revenue surprises of 11.83% and -0.95%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Perrigo Company plc (NYSE:PRGO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
This excerpt was brought to you by Argus Research using the Research Reports feature available through Yahoo Finance Premium. · Perrigo Company (PRGO), a longtime leader in OTC generics, had faced pressure over the past few years from industry-wide price erosion, challenges in its animal health business, and a reduction in FDA approvals. In addition, Perrigo sold its Animal Health business for $185 million.